Search Results for: Atox bio

Infection treatment now to target the kidneys

I reported previously (several times) on Israel’s Atox Bio and its Reltecimod treatment for Necrotizing Soft Tissue Infections. Atox Bio has just raised $30 million to fund trials of Reltecimod in Acute Kidney Injury patients, for which there is no … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

A new way to fight infection

The US Biomedical R&D Authority has awarded Israel’s Atox Bio $24 million to develop its treatments for severe infections.  Atox Bio’s AB103 uniquely modulates the patient’s immune response rather than attacking the virus or bacteria. Pathogens cannot develop resistance to … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

NSTI trials effective

Israel’s Atox Bio announced the success of Phase Iia clinical trials of its AB103 treatment of Necrotizing Soft Tissue Infections (NSTI). NSTIs are life-threatening bacterial infections with significant morbidity and high mortality rate. http://www.globes.co.il/serveen/globes/docview.asp?did=1000799752&fid=1725

Posted in Israel's Medical Achievements | Leave a comment

FDA fast-tracks Israeli tissues infection treatment

Israeli bio-tech Atox Bio announced that the US Food and Drug Administration has granted fast track designation to its lead product AB103, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI). Currently, there are no approved treatments … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Treating infections

Israel’s AtoxBio Ltd. has raised $3.5 million to finance a Phase II clinical trial for the effectiveness of its drug AB 103 for necrotizing soft tissue infections (NSTI). The drug has been granted fast-track orphan status by the US Food … Continue reading

Posted in Israel's Medical Achievements | Leave a comment